Page 239 - Read Online

Brooks et al. Neurological manifestations in Fabry disease

PERIPHERAL NEUROPATHY life for patients with FD.

Peripheral neuropathy has an important negative Financial support and sponsorship
impact on quality of life among FD patients. It has been Nil.
described as being present since the beginning of GL-3
deposition, i.e. from these patients’ first years of life. It Conflict of interest
affects both genders equally, and is often associated There are no conflicts of interest.
with fever and pain during exercise. The pain may last
for periods ranging from minutes up to several days, Patient consent
and may be incapacitating. [31-35] No patient involved.

As mentioned above regarding other neurological Ethics approval
manifestations of FD, the pathophysiological This article does not contain any studies with human
mechanisms of neuropathy are not fully understood participants or animals.
either. It has been proposed that inhibition of central
nociceptors would occur as a result of constant REFERENCES
activation of nociceptive afferents, in association
with neuronal dysfunction, Wallerian degeneration, 1. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman
M, Grabowski G, Packman S, Wilcox WR. Fabry disease, an under-
activation of the inflammatory cascade, vasa nervorum recognized multisystemic disorder: expert recommendations for
ischemia and molecular changes in the peripheral diagnosis, management, and enzyme replacement therapy. Ann Intern
nociceptor, similar to dying-back neuropathies. [36-40] Med 2003;138:338-46.
In addition, disproportion and dysfunction of axonal 2. Van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH,
sodium channels would increase the frequency of Linthorst GE, Hollak CE. A systematic review on screening for Fabry
nociceptive discharge. This last topic has practical disease: prevalence of individuals with genetic variants of unknown
importance, since pain treatment in these patients 3. significance. J Med Genet 2014;51:1-9.
Bowman MG, Rombach SM, Linthorst GE, Poorthuis BJ, Deprez
must be carried out using sodium channel-blocking RH, Aerts JM, Wijburg FA. Early cerebral manifestations in a young
drugs such as carbamazepine. Involvement of distal, female with Fabry disease with skewed X-inactivation. Clin Genet
small Aδ- myelinated fibers and C-unmyelinated 2011;80:500-2.
fibers is prevalent among patients with symptoms 4. Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA,
relating to temperature. It is important to establish a Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain DP.
uniform quantitative assessment battery for sensitive X-chromosome inactivation in female patients with Fabry disease.
symptoms. [41-45] Clin Genet 2016;89:44-54.
5. Rigoldi M, Concolino D, Morrone A, Pieruzzi F, Ravaglia R, Furlan
F, Santus F, Strisciuglio P, Torti G, Parini R. Intrafamilial phenotypic
ENZYME REPLACEMENT TREATMENT variability in four families with Anderson-Fabry disease. Clin Genet
2014;86:258-63.
Enzyme replacement therapy with humanized 6. Najafian B, Fogo AB, Lusco MA, Alpers CE. AJKD Atlas of Renal
recombinant α-Gal A (agalsidade beta, or more Pathology: fabry nephropathy. Am J Kidney Dis 2015;66:e35-6.
recently, agalsidase alpha) reduces the secondary 7. Frustaci A, Morgante E, Russo MA, Scopelliti F, Grande C, Verardo
R, Franciosa P, Chimenti C. Pathology and function of conduction
clinical events relating to FD by 60% to 80%. The tissue in Fabry disease cardiomyopathy. Circ Arrhythm Electrophysiol
effect of this enzyme replacement is seen in prevention 2015;8:799-805.
of cerebral, renal and cardiological life-threatening 8. Politei J, Thurberg BL, Wallace E, Warnock D, Serebrinsky G, Durand
events, which, in untreated patients, are responsible C, Schenone AB. Gastrointestinal involvement in Fabry disease. So
for more than 90% of deaths. [46,47] There is evidence important, yet often neglected. Clin Genet 2016;89:5-9.
that early treatment with enzyme replacement 9. Moore DF, Kaneski CR, Askari H, Schiffmann R. The cerebral
vasculopathy of Fabry disease. J Neurol Sci 2007;257:258-63.
therapy can stabilize vascular disease progression 10. Zarate YA, Hopkin RJ. Fabry’s disease. Lancet 2008;372:1427-35.
and decrease the risk of stroke. Patients may have 11. Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s
[48]
different response to treatment with agalsidade alpha disease. Ann Neurol 1996;40:8-17.
or beta. [49-51] 12. Utsumi K, Ueda K, Watanabe M, Sakamaki M, Arii K, Yamazaki M,
Komaba Y, Katsura K, Iino Y, Katayama Y. Thrombosis in Japanese
CONCLUSION patients with Fabry disease. J Neurol Sci 2009;283:83-5.
13. Altarescu G, Moore DF, Schiffmann R. Effect of genetic modifiers on
cerebral lesions in Fabry disease. Neurology 2005;64:2148-50.
Neurological manifestations of FD are often related to 14. Saarinen JT, Sillanpää N, Kantola I. A male Fabry disease patient
significant morbidity and mortality. Early detection and treated with intravenous thrombolysis for acute ischemic stroke. J
specific treatment of neurological involvement in cases Clin Neurosci 2015;2:423-5.
of α-Gal A deficiency may result in improved quality of 15. Moore DF, Herscovitch P, Schiffmann R. Selective arterial distribution
230 Neuroimmunology and Neuroinflammation ¦ Volume 3 ¦ October 28, 2016